Biomarkers · Liver & Nutritional

FIB-4 Index (NAFLD Fibrosis Score)

Lower values go with lower risk of death. Not measured in our NHANES panel. The curve is drawn from the published study (source below).

FIB-4 Index (NAFLD Fibrosis Score) and risk of death

Published curve higher than the NHANES fitNHANES fit higher

Risk of death relative to the curve's reference value, drawn from the published study (source below).

Published risk of death1.64×FIB-4 >=2.67 (presumed advanced hepatic fibrosis) vs FIB-4 <2.67 (95% CI 1.23–2.18) · KNHANES adults aged >=19 without viral hepatitis, cirrhosis, cancer, stroke, MI, angina or renal failure, Korea

FIB-4 Index (NAFLD Fibrosis Score) by age and sex

Each bar runs from the 5th to the 95th percentile, the darker part from the 25th to the 75th, and the tick is the median. Not a reference range or a target.

The percentiles as a table

Each row is one sex and age band: the values below which 5%, 25%, 50%, 75% and 95% of people fall (index), from the survey named in the row. Not a reference range or a target.
Sex	Age	5th	25th	Median	75th	95th	n	Cycle / source
All	20-39	0.29	0.41	0.52	0.67	1.06	1,427	NHANES 2017-2018
All	40-59	0.51	0.71	0.92	1.18	1.94	1,542	NHANES 2017-2018
All	60+	0.78	1.17	1.48	1.89	2.83	1,883	NHANES 2017-2018
All	all	0.35	0.58	0.88	1.32	2.27	4,852	NHANES 2017-2018
Men	20-39	0.31	0.44	0.56	0.70	1.15	682	NHANES 2017-2018
Men	40-59	0.54	0.76	0.98	1.27	2.04	717	NHANES 2017-2018
Men	60+	0.83	1.19	1.56	2.03	3.11	956	NHANES 2017-2018
Men	all	0.37	0.60	0.90	1.33	2.38	2,355	NHANES 2017-2018
Women	20-39	0.28	0.39	0.49	0.63	0.99	745	NHANES 2017-2018
Women	40-59	0.48	0.68	0.88	1.08	1.90	825	NHANES 2017-2018
Women	60+	0.75	1.15	1.44	1.80	2.57	927	NHANES 2017-2018
Women	all	0.34	0.55	0.86	1.29	2.16	2,497	NHANES 2017-2018

What studies found when this marker was changed

They describe what happened in those study groups, not a recommendation. See all catalogued interventions.

Measured changes in FIB-4 Index (NAFLD Fibrosis Score), study by study

1 effect with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.

Each row is one study: what was changed, the effect it reported on this marker, and the source.
Type	Intervention	Reported effect	Evidence	Source
nutraceutical	Silymarin 700 mg three times daily for 48 weeks in adults with biopsy-proven NASH (NAS >=4)	FIB-4 fell by 0.20 from baseline at 48 weeks (P = .041) vs a 0.18 increase with placebo (P = .389)	RCT	Wah Kheong C, et al. Clinical gastroenterology and hepatology : the official…

Sources

Risk curve: Seo YG 2023 (PMID 37164111): all-cause HR 1.64 (1.23-2.18) FIB-4 >=2.67 (presumed advanced hepatic fibrosis) vs FIB-4 <2.67. Scaled to US values (NHANES).
Seo YG, Polyzos SA, Park KH, Mantzoros CS. Fibrosis-4 Index Predicts Long-Term All-Cause, Cardiovascular and Liver-Related Mortality in the Adult Korean Population. Clinical Gastroenterology and Hepatology. 2023;21(13):3322-3335.

Map FIB-4 Index (NAFLD Fibrosis Score) against another biomarker.

Map FIB-4 Index (NAFLD Fibrosis Score) against another marker